Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDMC plus R21/Matrix-M vaccination in children after severe malaria or severe anaemia
PACTR202607921693996Phase 2Not yet recruiting
- Sponsor
- Kumasi Centre for Collaborative Research in Tropical Medicine
- Start
- Dec 2026
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of R21/Matrix-M and dihydroartemisinin + piperaquine in malaria (3 arms), sponsored by Kumasi Centre for Collaborative Research in Tropical Medicine. Primary endpoints: Primary outcome: anti-NANP IgG geometric mean titer at Day 84, Superiority comparison and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
R21/Matrix-Mdihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202607921693996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607921693996.